Level structures of 95,97Mo — A comparative study

High-spin states of ^95,97Mo (Z=42, N=53,55) nuclei have been investigated through ⁸²Se(¹⁸O, xn) reaction at Eb=60 MeV. The level scheme in ⁹⁵Mo has been observed upto ≏ 10 MeV in the present experiment. The level structure shows mainly single particle character. In ⁹⁷Mo, the ground state level sequence has been extended to ≏ 4.5 MeV while the previous information had been up to 2.4 MeV. A negative parity band built on 1437 keV (11/2⁻) excited state has been extended to 5.5 MeV. The structure seems to show a coexistence of single particle and collective modes of excitation. Properties of both the nuclei have been compared with shell model calculations using OXBASH.     

Development of a universal measure of quadrupedal forelimb-hindlimb coordination using digital motion capture and computerised analysis

Background  

Clinical spinal cord injury in domestic dogs provides a model population in which to test the efficacy of putative therapeutic interventions for human spinal cord injury. To achieve this potential a robust method of functional analysis is required so that statistical comparison of numerical data derived from treated and control animals can be achieved.     

Determination of absolute configuration of chiral hemicage metal complexes using time-dependent density functional theory

Time-dependent density functional theory (TD-DFT) is applied to the UV-vis absorption and circular dichroism (CD) spectra of a series of transition metals (M=Ru, Zn, Fe) complexed with an enantiopure hemicage ligand, (-)-(5R,5'R,5' 'R,7R,7'R,7' 'R,8S,8'S,8' 'S)-8,8',8' '-[(2,4,6-trimethyl-1,3,5-benzenetriyl)tris(methylene)]tris[5,6,7,8-tetrahydro-6,6-dimethyl-3-(2-pyridinyl)-5,7-methanoisoquinoline (1). The electronic spectra of the Ru and Fe complexes contain two regions, one featuring low-energy 1MLCT transitions and the other higher energy 1LC transitions; the Zn analog possesses only the 1LC transitions due to its filled 3d shell. TD-DFT is able to identify correctly these transitions in the spectra, as well as to reproduce experimental spectra accurately, with regard to both the transition energies and the relative intensities of the different transitions. Additionally, it is possible to use TD-DFT to assign the absolute configuration at the metal center with high confidence by matching the experimental and calculated spectra.     

Catalytic protein modification with dirhodium metallopeptides: specificity in designed and natural systems

In this study, we present advances in the use of rhodium(II) metallopeptides for protein modification. Site-specific, proximity-driven modification is enabled by the unique combination of peptide-based molecular recognition and a rhodium catalyst capable of modifying a wide range of amino-acid side chains. We explore catalysis based on coiled-coil recognition in detail, providing an understanding of the determinants of specificity and culminating in the demonstration of orthogonal modification of separate proteins in cell lysate. In addition, the concepts of proximity-driven catalysis are extended to include modification of the natural Fyn SH3 domain with metallopeptides based on a known proline-rich peptide ligand. The development of orthogonal catalyst-substrate pairs for modification in lysate, and the extension of these methods to new natural protein domains, highlight the capabilities for new reaction design possible in chemical approaches to site-specific protein modification.     

A designer bleomycin with significantly improved DNA cleavage activity

The bleomycins (BLMs) are used clinically in combination with a number of other agents for the treatment of several types of tumors, and the BLM, etoposide, and cisplatin treatment regimen cures 90-95% of metastatic testicular cancer patients. BLM-induced pneumonitis is the most feared, dose-limiting side effect of BLM in chemotherapy, which can progress into lung fibrosis and affect up to 46% of the total patient population. There have been continued efforts to develop new BLM analogues in the search for anticancer drugs with better clinical efficacy and lower lung toxicity. We have previously cloned and characterized the biosynthetic gene clusters for BLMs from Streptomyces verticillus ATCC15003, tallysomycins from Streptoalloteichus hindustanus E465-94 ATCC31158, and zorbamycin (ZBM) from Streptomyces flavoviridis SB9001. Comparative analysis of the three biosynthetic machineries provided the molecular basis for the formulation of hypotheses to engineer novel analogues. We now report engineered production of three new analogues, 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z and the evaluation of their DNA cleavage activities as a measurement for their potential anticancer activity. Our findings unveiled: (i) the disaccharide moiety plays an important role in the DNA cleavage activity of BLMs and ZBMs, (ii) the ZBM disaccharide significantly enhances the potency of BLM, and (iii) 6'-deoxy-BLM Z represents the most potent BLM analogue known to date. The fact that 6'-deoxy-BLM Z can be produced in reasonable quantities by microbial fermentation should greatly facilitate follow-up mechanistic and preclinical studies to potentially advance this analogue into a clinical drug.